Evidence map›Paper›PMID 39739284›Full record

ArticleAIDS and behavior2025

Willingness to Use Oral and Long-Acting Injectable PrEP in Substance-Using Men who have Sex with Men (SU-MSM) in High HIV Incidence Southern U.S. Cities: A NIDA Clinical Trials Network Study.

Susan Tross, Tanja C Laschober, Margaret Paschen-Wolff, Melissa Ertl, C Mindy Nelson, Lynette Wright, Chloe Lancaster, Daniel J Feaster, Mauda Monger, Phil Toal and 11 more

Abstract read
In one paragraph

Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Comorbidities of substance use: Opportunities realized and future needs.Journal of substance use and addiction treatment · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Susan TrossColumbia University Irving Medical Center, New York, NY, USA. st130@cumc.columbia.edu.
Tanja C LaschoberUniversity of Washington Addictions, Drug & Alcohol Institute, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA.
Margaret Paschen-WolffColumbia University Irving Medical Center, New York, NY, USA.
Melissa ErtlPresent address: Department of Psychology, University of Minnesota, Minneapolis, MN, USA.
C Mindy NelsonDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Lynette WrightUniversity of Washington Addictions, Drug & Alcohol Institute, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA.
Chloe LancasterDepartment of Leadership, Policy, and Lifelong Learning, University of South Florida, Tampa, FL, USA.
Daniel J FeasterDepartment of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Mauda MongerMy Brother's Keeper, Ridgeland, MS, USA.
Phil ToalAspire Health Partners, HIV Services, Orlando, FL, USA.
Joshua P FegleyCrescent Care, New Orleans, LA, USA.
David MecheOpen Health Care Clinic, Baton Rouge, LA, USA.
Colby HankeyAspire Health Partners, HIV Services, Orlando, FL, USA.
Christina WoodhouseJasmyn, Jacksonville, FL, USA.
Anya SpectorStella and Charles Guttman Community College, City University of New York, New York, NY, USA.
Lauren DresserThe Emmes Company, LLC, Rockville, MD, USA.
Landhing MoranCenter for the Clinical Trials Network, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Eve JelstromThe Emmes Company, LLC, Rockville, MD, USA.
Louise HaynesMedical University of South Carolina, Charleston, SC, USA.
Steven ShoptawUniversity of California at Los Angeles, Los Angeles, CA, USA.
Mary A HatchUniversity of Washington Addictions, Drug & Alcohol Institute, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sung-Jae Lee · 1997 to 2026
$53.5M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MILTON L WAINBERG · 2003 to 2026
$48.2M
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN) HEAL STUDIES. POP 2/26/24 - 8/25/2475N95020D00012 · NIDA · THE EMMES COMPANY, LLC · PI JELSTROM, EVE · 2020 to 2025
$40.5M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
INSPIRE : Interdisciplinary Social and Behavioral Science Prevention and Intervention REsearch in HIVT32MH019139 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Claude Ann Mellins, Jae M. Sevelius · 1989 to 2026
$10.8M
Enhanced Interdisciplinary Research Training InstituteR25DA050687 · NIDA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VALDEZ, AVELARDO · 2020 to 2024
$1.3M
NIDA NIH HHS 75N95020D00012NIDA NIH HHS R25 DA050687NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIDDK NIH HHS R25 DA050687-01A1NIH HHS HHSN271201400028CNIH HHS P30-MH43520NIH HHS T32 MH019139NIH HHS UG1DA013035NIH HHS UG1DA013714NIMH NIH HHS P30 MH043520NIMH NIH HHS P30 MH058107NIMH NIH HHS T32 MH019139
6 · The paper itself

Abstract

In Southern U.S. states with high HIV incidence and low HIV Pre-Exposure Prophylaxis (PrEP) uptake, enhanced efforts to increase interest in and willingness to use PrEP are needed. This implementation survey examined the associations of sociodemographic background, substance use, and sexual risk behaviors with willingness to use daily oral and long-acting injectable (LAI) PrEP among substance using men who have sex with men (SU-MSM). Participants were 225 SU-MSM recruited from sexually transmitted infection (STI) clinics, syringe services programs (SSPs), and substance use treatment programs (SUTPs) in eight Southern U.S. cities. Rates of willingness were high for both daily oral PrEP (78%) and LAI PrEP (66%). In multivariable analyses, distinct factors were associated with willingness towards each. For daily oral PrEP, greater willingness was associated with condomless anal sex, less frequent non-injection opioid use, prior PrEP awareness, and past use of PrEP. For LAI PrEP, greater willingness was associated with Black race, identifying as gay, being single, and higher injection drug use frequency. Lower willingness to use LAI PrEP was associated with higher non-injection opioid use frequency. Findings about willingness to use LAI PrEP, as a relatively newer modality, and greater willingness among Black SU-MSM as a disproportionately HIV-impacted population, are especially important. These findings argue for the necessity to enhance PrEP promotion efforts that distinguish between oral and LAI PrEP and that are specifically tailored to major SU-MSM subgroups in the Southern U.S.

Indexed as

Anti-HIV AgentsHIV InfectionsHomosexuality, MalePatient Acceptance of Health CarePre-Exposure ProphylaxisSubstance-Related DisordersAdministration, OralAdultCitiesHumansIncidenceInjectionsMaleMiddle AgedRisk-TakingSexual and Gender MinoritiesAnti-HIV AgentsHIV riskMSMPrEPSouthern United StatesSubstance use

Identifiers

PMID39739284
PMCPMC12977088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.